Physician profile
Umer Shoukat
NPI 1316394158
$523.26
in general payments reported to CMS, 2019-2025
13 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.06 · 2022: $15.97 · 2023: $51.36 · 2024: $106 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $148.79 | 2024-2025 | Nucala, Trelegy Ellipta |
| Harmony Biosciences LLC | $99.99 | 2025 | |
| Olympus Corporation of The Americas | $60.00 | 2024 | |
| Axsome Therapeutics, INC. | $46.51 | 2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2025 | Dupixent |
| Verona Pharma, INC. | $22.35 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $21.41 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $19.29 | 2023 | Lumryz |
| Mylan Specialty L.P. | $19.03 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $17.15 | 2025 | Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $15.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.04 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Shoukat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.